Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD
Toggle Summary KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
Toggle Summary KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing